These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28112422)

  • 1. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.
    Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y
    Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
    Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
    Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
    Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
    Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
    Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
    Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
    Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
    Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    Yoodee J; Permsuwan U; Nimworapan M
    Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
    Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
    Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
    Vig S; Seibert L; Green MR
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting.
    Liu G; Jin Y; Jiang Y; Zhao J; Jiang C; Zhang Z; Zhao L; Li H; Chen F; Wang J; Fan H; Li Z; Jia Y; Jin G; Li Q
    Int J Clin Pract; 2022; 2022():5954379. PubMed ID: 36128262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    He M; Xu R; Liu M; Zhang Y; Yi F; Wei Y; Liu Q; Zhang W
    Ann Palliat Med; 2021 Apr; 10(4):4308-4319. PubMed ID: 33894731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
    Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
    Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
    dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
    J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
    Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
    Hocking CM; Kichenadasse G
    Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.